Oric Pharmaceuticals Inc
NASDAQ:ORIC
Income Statement
Earnings Waterfall
Oric Pharmaceuticals Inc
Income Statement
Oric Pharmaceuticals Inc
| Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||||||
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | |||||||||||||||||||||||||
| Operating Expenses |
(29)
|
(31)
|
(36)
|
(42)
|
(49)
|
(82)
|
(91)
|
(72)
|
(79)
|
(86)
|
(85)
|
(92)
|
(92)
|
(94)
|
(98)
|
(101)
|
(111)
|
(114)
|
(125)
|
(134)
|
(143)
|
(146)
|
(149)
|
(148)
|
|
| Selling, General & Administrative |
(6)
|
(7)
|
(9)
|
(11)
|
(13)
|
(16)
|
(19)
|
(20)
|
(22)
|
(24)
|
(25)
|
(25)
|
(25)
|
(25)
|
(24)
|
(24)
|
(26)
|
(26)
|
(27)
|
(28)
|
(29)
|
(30)
|
(31)
|
(32)
|
|
| Research & Development |
(23)
|
(25)
|
(28)
|
(31)
|
(36)
|
(40)
|
(48)
|
(52)
|
(57)
|
(62)
|
(60)
|
(67)
|
(67)
|
(69)
|
(74)
|
(77)
|
(85)
|
(88)
|
(98)
|
(107)
|
(114)
|
(117)
|
(118)
|
(116)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
(25)
|
(25)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Operating Income |
(29)
N/A
|
(31)
-10%
|
(36)
-15%
|
(42)
-15%
|
(49)
-18%
|
(82)
-65%
|
(91)
-12%
|
(72)
+21%
|
(79)
-9%
|
(86)
-9%
|
(85)
+0%
|
(92)
-8%
|
(92)
+1%
|
(94)
-3%
|
(98)
-5%
|
(101)
-3%
|
(111)
-9%
|
(114)
-3%
|
(125)
-10%
|
(134)
-7%
|
(143)
-6%
|
(146)
-2%
|
(149)
-2%
|
(148)
+1%
|
|
| Pre-Tax Income | |||||||||||||||||||||||||
| Interest Income Expense |
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
3
|
4
|
6
|
8
|
10
|
12
|
14
|
15
|
15
|
14
|
12
|
13
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
(13)
|
(25)
|
0
|
0
|
(12)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Pre-Tax Income |
(27)
N/A
|
(30)
-11%
|
(35)
-17%
|
(54)
-55%
|
(74)
-37%
|
(81)
-10%
|
(91)
-12%
|
(84)
+8%
|
(79)
+7%
|
(85)
-8%
|
(85)
+1%
|
(91)
-8%
|
(89)
+2%
|
(90)
-1%
|
(93)
-3%
|
(93)
-1%
|
(101)
-8%
|
(102)
-1%
|
(111)
-9%
|
(120)
-9%
|
(128)
-6%
|
(133)
-4%
|
(138)
-3%
|
(135)
+2%
|
|
| Net Income | |||||||||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(27)
|
(30)
|
(35)
|
(54)
|
(74)
|
(81)
|
(91)
|
(84)
|
(79)
|
(85)
|
(85)
|
(91)
|
(89)
|
(90)
|
(93)
|
(93)
|
(101)
|
(102)
|
(111)
|
(120)
|
(128)
|
(133)
|
(138)
|
(135)
|
|
| Net Income (Common) |
(27)
N/A
|
(30)
-11%
|
(35)
-17%
|
(54)
-55%
|
(74)
-37%
|
(81)
-10%
|
(91)
-12%
|
(84)
+8%
|
(79)
+7%
|
(85)
-8%
|
(85)
+1%
|
(91)
-8%
|
(89)
+2%
|
(90)
-1%
|
(93)
-3%
|
(93)
-1%
|
(101)
-8%
|
(102)
-1%
|
(111)
-9%
|
(120)
-9%
|
(128)
-6%
|
(133)
-4%
|
(138)
-3%
|
(135)
+2%
|
|
| EPS (Diluted) |
-0.98
N/A
|
-0.99
-1%
|
-1.16
-17%
|
-1.77
-53%
|
-3.36
-90%
|
-2.21
+34%
|
-2.48
-12%
|
-2.15
+13%
|
-2.07
+4%
|
-2.16
-4%
|
-2.15
+0%
|
-2.31
-7%
|
-2.25
+3%
|
-1.99
+12%
|
-2.02
-2%
|
-1.62
+20%
|
-1.96
-21%
|
-1.51
+23%
|
-1.58
-5%
|
-1.69
-7%
|
-1.83
-8%
|
-1.88
-3%
|
-1.76
+6%
|
-1.36
+23%
|
|